UP!

CBMX $6.25   View long term graphs

CombiMatrix Corp.
Type
Public
Traded as NASDAQ: CBMX
Industry Genetic testing
Headquarters Irvine, CA, United States
Key people
Mark McDonough (CEO), Scott Burell (CFO), Weslie Tyson (CMO)
Products CombiSNP Array Prenatal, CombiSNP for Miscarriage Analysis, CombiSNP for Pediatric and Postnatal Analysis
Services SNP Miscarriage Analysis for Recurrent Pregnancy Loss, Prenatal Analysis, Pediatric Analysis
Website www.combimatrix.com

CombiMatrix Corp. (NASDAQ: CBMX) CombiMatrix is a clinical diagnostic laboratory specializing in pre-implantation genetic screening, miscarriage analysis, prenatal and pediatric diagnostics, offering DNA-based testing for the detection of genetic abnormalities beyond what can be identified through traditional methodologies. As a full-scale cytogenetic and cytogenomic laboratory, CombiMatrix performs genetic testing utilizing a variety of advanced cytogenomic techniques, including chromosomal microarray analysis, standardized and customized fluorescence in situ hybridization (FISH) and high-resolution karyotyping. CombiMatrix is dedicated to providing high-level clinical support for healthcare professionals in order to help them incorporate the results of complex genetic testing into patient-centered medical decision making.

In 2012 CombiMatrix shifted its focus from providing oncology genetic testing to developmental testing. Their focus is cytogenomic miscarriage analysis, prenatal analysis and postnatal/pediatric analysis.

CombiMatrix uses the CombiSNP Array as their technology platform. SNP stands for Single nucleotide polymorphism probes. These probes allow for increased precision and greater diagnostic yield. This array contains more than 845,000 SNP markers covering both coding and non-coding human genome sequences. The median spatial resolution between probes is 1 Kb within gene rich regions and 5 Kb outside of gene-rich regions.

News

Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2017 2018-02-21 Future report Set alerts
Q3 2017 2018-02-21 Future report Set alerts
Q2 2017 2017-08-03 -0.13 -0.13
Q1 2017 2017-05-04 -0.19 -0.19
Q4 2016 2017-02-22 -0.22 -0.22
Q3 2016 2016-11-02 -0.38 -0.38
Q2 2016 2016-08-03 -0.89 -0.89
Q1 2016 2016-05-04 -1.73 -3.63
Q4 2015 2016-02-17 -1.82 -1.95
Q3 2015 2015-11-04 -1.80 -1.95

Ratings

7742-03-21
7679-03-07
6213-02-14
4829-03-19
3389-02-26
2046-03-31
2009-09-28
2009-04-02 Initiated Benchmark Buy $15
2008-09-03 Initiated Dawson James Buy $17.50
1970-01-01
0574-03-09
7742-03-21
7679-03-07
6213-02-14
4829-03-19
3389-02-26

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Funds

In CBMX 1 funds of 2183 total. Show all

Fund name Ticker shares
BlackRock Fund Advisors 8019

Major Shareholders

Name Relationship Total Shares Holding stocks
HAMILTON EDWARD ARTHUR 15.62%  (1728457) CBMX /
McGowan Mark Interim President and CEO 2.09%  (230918) CBMX / PRXI /
AKIN THOMAS B 1.07%  (118418) CBMX / DX / IMH /
KUMAR AMIT PRESIDENT AND CEO 0.85%  (94398) ASTI / CBMX / ITUS /
ANDERSON BROOKE P Chief Operating Officer 0.29%  (32348) CBMX /
Ding Richard 0.16%  (17495) CBMX /
FORCHE DANIEL R Sr VP of Sales and Marketing 0.10%  (11399) CBMX /
ABELES JOHN H 0.08%  (9119) CBMX /
Tyson Robert Weslie Chief Medical Officer 0.07%  (7500) CBMX /
Gottlieb Scott 0.04%  (4804) CBMX /
Hockett Richard Jr Chief Medical Officer 0.01%  (1000) CBMX /

Comments